Daniel M Girardi

7PUBLICATIONS
84CO-AUTHORS
Epidemiological modellingPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Chemotherapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Oct 22, 2026
Impact of a New Episodic Radiotherapy Reimbursement Model on Treatment Funding and Utilization: A 5-Year Retrospective Analysis in the Brazilian Public Health System.

|Jun 17, 2026
Tumor regression pattern and distribution of residual tumor cells in potential candidates for local excision of rectal cancer: a prospective cohort study.

|Jul 02, 2024
Final Results From a Phase I Trial and Expansion Cohorts of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced/Metastatic Genitourinary Tumors.

Andrea B Apolo, Daniel M Girardi, Scot A Niglio

|Apr 09, 2024
Advanced renal cell carcinoma management: the Latin American Cooperative Oncology Group (LACOG) and the Latin American Renal Cancer Group (LARCG) consensus update.

Andrey Soares, Fernando Sabino Marques Monteiro, Karine Martins da Trindade

|Jan 15, 2022
Cabozantinib plus Nivolumab Phase I Expansion Study in Patients with Metastatic Urothelial Carcinoma Refractory to Immune Checkpoint Inhibitor Therapy.

Daniel M Girardi, Scot A Niglio, Amir Mortazavi

|Sep 11, 2020
Phase I Study of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced or Metastatic Urothelial Carcinoma and Other Genitourinary Tumors.

Andrea B Apolo, Rosa Nadal, Daniel M Girardi

Pageof 2

Frequent Collaborators

3 joint publications

Amir Mortazavi

3 joint publications

Donald P Bottaro

3 joint publications

Seth M Steinberg

3 joint publications

Rosa Nadal